MANCO Project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003651
05 May
A neutralizing monoclonal antibody has been identified
The MANCO consortium has reached an important milestone! The MANCO team has been searching for broadly neutralizing human monoclonal antibodies to treat COVID-19. We identified a broadly reactive SARS-CoV-2 – 87G7 – that potently neutralized Omicron and other variants of concern. Moreover we demonstrated that 87G7 can provide protection against infection with these SARS-CoV-2 variants
MANCO Project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003651
